Thomas Waldmann

Thomas Waldmann is Co-chief of the Lymphoid Malignancies Branch at the National Cancer Institute.

 

Content by Thomas Waldmann:

 Research Field Immunology

The Second Coming of Daclizumab

| Thomas Waldmann

Dropped as an anti-rejection drug, daclizumab is back with a new indication in MS
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register

October Issue of The Translational Scientist